Table 4 –
Multivariable Cox regression analysis predicting clinical recurrence after SLND in 654 patients treated for nodal recurrence of prostate cancer
Predictor | HR | 95% CI | p value |
---|---|---|---|
Gleason grade group | |||
≤4 | 1.00 | Ref. | – |
5 | 2.04 | 1.66–2.50 | <0.0001 |
Time from RP to PSA rising, per 6 mo | 0.98 | 0.96–0.99 | 0.025 |
HT administration at the time of PET/CT scan | |||
No | 1.00 | Ref. | – |
Yes | 1.47 | 1.19–1.82 | 0.0005 |
Retroperitoneum involvement at PET/CT scan | |||
No | 1.00 | Ref. | – |
Yes | 1.24 | 1.01–1.52 | 0.038 |
Positive spots at PET/CT scan | |||
≤2 | 1.00 | Ref. | – |
≥3 | 1.26 | 1.05–1.61 | 0.019 |
PSA at SLND, ng/ml | 1.05 | 1.04–1.07 | <0.0001 |
CI = confidence interval; HR = hazard ratio; HT = hormonal therapy; PET/CT = positron emission tomography/computed tomography; PSA = prostate-specific antigen; Ref. = reference; RP = radical prostatectomy; SLND = salvage lymph node dissection.